Andrew Guggenhime - Mar 1, 2023 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role: President and CFO
Signature: Andrew Guggenhime, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol: PCVX
Transactions as of: Mar 1, 2023
Transactions value $: -$71,653
Form type: 4
Date filed: 3/3/2023, 04:09 PM
Previous filing: Feb 23, 2023
Next filing: Sep 6, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCVX	Common Stock	Award	$0	+22.5K	+36.75%	$0.00	83.7K	Mar 1, 2023	Direct	F1
transaction	PCVX	Common Stock	Tax liability	-$71.7K	-1.73K	-2.06%	$41.49	82K	Mar 2, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCVX	Stock Option (right to buy)	Award	$0	+135K		$0.00	135K	Mar 1, 2023	Common Stock	135K	$41.67	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2023 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
F2	Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units.
F3	1/48 of shares subject to the option vest on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.